Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for neurological diseases. Co. is focused on developing the following product candidates: LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies; LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator in preclinical studies for multiple neurological diseases; and LP143, a centrally acting, full cannabinoid type 2 receptor agonist in preclinical studies for central nervous system diseases and disorders. We show 13 historical shares outstanding datapoints in our coverage of LBPH's shares outstanding history.
Understanding the changing numbers of LBPH shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like LBPH versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching LBPH by allowing them to research LBPH shares outstanding history
as well as any other stock in our coverage universe. |
Free LBPH Email Alerts:
Video: Shares Outstanding Importance
